Dr. Paul Parren - Gilde Healthcare

team
Venture&Growth

All team members
Dr. Paul Parren
Operational Partner
The Netherlands

Dr. Paul Parren

Operational Partner

Paul Parren is an internationally recognized antibody drug innovator and developer. Paul was Head of Preclinical Development and Research at Genmab (2002-2017), translating antibody biology successfully into immunotherapies from discovery to the clinic, including approved therapeutic antibodies ofatumumab and daratumumab, as well as establishing validated antibody platform technologies. He is a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden, the Netherlands, board member of The Antibody Society and was an Associate Professor at The Scripps Research Institute in La Jolla, California. He holds a PhD in Molecular Immunology from the University of Amsterdam.

Paul assists Gilde in the evaluation of investment opportunities and is also acting as Executive Vice President and Head of Research & Development for Gilde’s portfolio company Lava Therapeutics.

Joep Muijrers

General Partner Public Investments
Venture&Growth
Joep Muijrers joined Gilde in 2021 with two decades of broad experience in life sciences, including senior roles in portfolio management, company operations and investment banking. Most recently, he served as Chief Financial Officer and...

Janke Dittmer

General Partner Healthtech
Venture&Growth
Janke Dittmer joined Gilde in 2011 as a Partner. He led Gilde's investment in Definiens (acquired by AZ), Sapiens (acquired by Medtronic), Volta Medical, Big Health, FIRE1, Lumeon and Nyxoah and was involved in several...

Stefan Luzi

Partner Therapeutics
Venture&Growth
Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Lava Therapeutics B.V....